Author:
Grund Andrea,Sinha Manish D.,Haffner Dieter,Leifheit-Nestler Maren
Abstract
Cardiovascular diseases (CVD) are a hallmark in pediatric patients with chronic kidney disease (CKD) contributing to an enhanced risk of all-cause and CV morbidity and mortality in these patients. The bone-derived phosphaturic hormone fibroblast growth factor (FGF) 23 progressively rises with declining kidney function to maintain phosphate homeostasis, with up to 1,000-fold increase in patients with kidney failure requiring dialysis. FGF23 is associated with the development of left ventricular hypertrophy (LVH) and thereby accounts to be a CVD risk factor in CKD. Experimentally, FGF23 directly induces hypertrophic growth of cardiac myocytes in vitro and LVH in vivo. Further, clinical studies in adult CKD have observed cardiotoxicity associated with FGF23. Data regarding prevalence and determinants of FGF23 excess in children with CKD are limited. This review summarizes current data and discusses whether FGF23 may be a key driver of LVH in pediatric CKD.
Subject
Pediatrics, Perinatology and Child Health
Reference130 articles.
1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification;Levey;Am J Kidney Dis.,2002
2. Cause of death in patients with reduced kidney function;Thompson;JASN.,2015
3. Cardiorenal syndrome type 4: a review;Clementi;Cardiorenal Med.,2013
4. Cardiorenal syndrome type 4: from chronic kidney disease to cardiovascular impairment;Granata;Eur J Intern Med.,2016
5. Pathophysiology of the cardio-renal syndromes types 1-5: an uptodate;Di Lullo;Indian Heart J.,2017
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献